Literature DB >> 33269427

Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.

C Christofer Juhlin1,2, Lori A Erickson3.   

Abstract

The majority of parathyroid disease encountered in routine practice is due to single parathyroid adenoma, of which the majority arise as sporadic tumors. This is usually a straightforward diagnosis in endocrine pathology when in the appropriate clinical setting, although subsets of cases will exhibit atypical histological features that may warrant additional immunohistochemical and genetic analyses to estimate the malignant potential. Parathyroid carcinomas on the other hand, are bona fide malignant tumors characterized by their unequivocal invasion demonstrated through routine histology or metastasis. The ultimate endpoint for any molecular marker discovered through laboratory investigations is to be introduced in clinical routine practice and guide the surgical pathologist in terms of diagnostics and prognostication. For parathyroid tumors, the two main diagnostic challenges include the distinction between parathyroid adenoma and parathyroid carcinoma, as well as the pinpointing of hereditable disease for familial screening purposes. While numerous markers on genetic, epigenetic, and protein levels have been proposed as discriminative in these aspects, this review aims to condense the scientific coverage of these enigmatic topics and to propose a focused surgical pathology approach to the subject.

Entities:  

Keywords:  Genetics; Parathyroid tumors; Pathology; Primary hyperparathyroidism; Review

Year:  2020        PMID: 33269427      PMCID: PMC7960610          DOI: 10.1007/s12022-020-09656-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  159 in total

Review 1.  Clinical review 122: Parathyroid carcinoma.

Authors:  E Shane
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study.

Authors:  M A Vasef; R K Brynes; M Sturm; C Bromley; R A Robinson
Journal:  Mod Pathol       Date:  1999-04       Impact factor: 7.842

3.  CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.

Authors:  Michael A Hahn; Viive M Howell; Anthony J Gill; Adele Clarkson; Graham Weaire-Buchanan; Bruce G Robinson; Leigh Delbridge; Oliver Gimm; Wolfgang D Schmitt; Bin T Teh; Deborah J Marsh
Journal:  Endocr Relat Cancer       Date:  2010-02-18       Impact factor: 5.678

4.  Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.

Authors:  Geoffrey E Woodard; Ling Lin; Jian-Hua Zhang; Sunita K Agarwal; Stephen J Marx; William F Simonds
Journal:  Oncogene       Date:  2005-02-10       Impact factor: 9.867

5.  Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome.

Authors:  Leelamma M Panicker; Jian-Hua Zhang; Pradeep K Dagur; Matthew J Gastinger; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2010-05-18       Impact factor: 5.678

6.  Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease.

Authors:  F Farnebo; G Auer; L O Farnebo; B T Teh; S Twigg; U Aspenblad; N W Thompson; L Grimelius; C Larsson; K Sandelin
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

7.  p27(kip1) and Other Cell-Cycle Protein Expression in Normal and Neoplastic Endocrine Tissues.

Authors:  Lori A. Erickson
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

8.  Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas.

Authors:  Simona Borsari; Elena Pardi; Natalia S Pellegata; Misu Lee; Federica Saponaro; Liborio Torregrossa; Fulvio Basolo; Elena Paltrinieri; Maria Chiara Zatelli; Gabriele Materazzi; Paolo Miccoli; Claudio Marcocci; Filomena Cetani
Journal:  Endocrine       Date:  2016-04-02       Impact factor: 3.633

9.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

Authors:  L M Mulligan; C Eng; C S Healey; D Clayton; J B Kwok; E Gardner; M A Ponder; A Frilling; C E Jackson; H Lehnert
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

Review 10.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

View more
  10 in total

1.  Special Issue on Molecular Pathology of Endocrine Neoplasms: Understanding the Basis of Endocrine Pathology Practice.

Authors:  Ozgur Mete
Journal:  Endocr Pathol       Date:  2021-03       Impact factor: 3.943

2.  Association of Famine Exposure on the Changing Clinical Phenotypes of Primary Hyperparathyroidism in 20 years.

Authors:  Tian-Jiao Yuan; Yu-Ying Yang; Min-Ting Zhu; Yang He; Lin Zhao; Wen-Zhong Zhou; Ting-Wei Su; Hong-Yan Zhao; Li-Hao Sun; Bei Tao; Jian-Min Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

Review 3.  Histone Modification on Parathyroid Tumors: A Review of Epigenetics.

Authors:  Luiz C Conti de Freitas; Rogerio M Castilho; Cristiane H Squarize
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

Review 4.  Metabolic Bone Diseases and New Drug Developments.

Authors:  Vijayakumar Natesan; Sung-Jin Kim
Journal:  Biomol Ther (Seoul)       Date:  2022-03-28       Impact factor: 4.231

5.  Parathyroid Adenoma With Respiratory-Like Epithelium: Case Report of a Potential Mimic With Unknown Etiology.

Authors:  C Christofer Juhlin; Jan Zedenius
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-04       Impact factor: 5.555

6.  Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center.

Authors:  L Samuel Hellgren; Adam Stenman; Johan O Paulsson; Anders Höög; Catharina Larsson; Jan Zedenius; C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2022-03-19       Impact factor: 4.056

7.  Preoperative inflammatory markers for predicting parathyroid carcinoma.

Authors:  Keiko Ohkuwa; Kiminori Sugino; Ryohei Katoh; Mitsuji Nagahama; Wataru Kitagawa; Kenichi Matsuzu; Akifumi Suzuki; Chisato Tomoda; Kiyomi Hames; Junko Akaishi; Chie Masaki; Kana Yoshioka; Koichi Ito
Journal:  Endocr Connect       Date:  2022-07-14       Impact factor: 3.221

8.  Analyzing Genetic Differences Between Sporadic Primary and Secondary/Tertiary Hyperparathyroidism by Targeted Next-Generation Panel Sequencing.

Authors:  Yu Ah Hong; Ki Cheol Park; Bong Kyun Kim; Jina Lee; Woo Young Sun; Hae Joung Sul; Kyung-Ah Hwang; Won Jung Choi; Yoon-Kyung Chang; Suk Young Kim; Soyoung Shin; Joonhong Park
Journal:  Endocr Pathol       Date:  2021-07-03       Impact factor: 3.943

9.  Distinguishing Parathyromatosis, Atypical Parathyroid Adenomas, and Parathyroid Carcinomas Utilizing Histologic and Clinical Features.

Authors:  Jefree J Schulte; Garrison Pease; Jerome B Taxy; Curtis Hall; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2021-01-04

10.  Parafibromin Abnormalities in Ossifying Fibroma.

Authors:  Jessica Costa-Guda; Chetanya Pandya; Maya Strahl; Patricia Taik; Robert Sebra; Rong Chen; Andrew V Uzilov; Andrew Arnold
Journal:  J Endocr Soc       Date:  2021-05-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.